200 related articles for article (PubMed ID: 30460772)
21. Histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in clear cell sarcoma models.
Liu S; Cheng H; Kwan W; Lubieniecka JM; Nielsen TO
Mol Cancer Ther; 2008 Jun; 7(6):1751-61. PubMed ID: 18566246
[TBL] [Abstract][Full Text] [Related]
22. The relative activity of cisplatin, oxaliplatin and satraplatin in testicular germ cell tumour sensitive and resistant cell lines.
Perry J; Powles T; Shamash J; Veerupillai A; McGrowder E; Noel E; Lu YJ; Oliver T; Joel S
Cancer Chemother Pharmacol; 2009 Oct; 64(5):925-33. PubMed ID: 19263053
[TBL] [Abstract][Full Text] [Related]
23. Regulation of tissue factor in NT2 germ cell tumor cells by cisplatin chemotherapy.
Jacobsen C; Oechsle K; Hauschild J; Steinemann G; Spath B; Bokemeyer C; Ruf W; Honecker F; Langer F
Thromb Res; 2015 Sep; 136(3):673-81. PubMed ID: 26205155
[TBL] [Abstract][Full Text] [Related]
24. Activity of nintedanib in germ cell tumors.
Steinemann G; Jacobsen C; Gerwing M; Hauschild J; von Amsberg G; Höpfner M; Nitzsche B; Honecker F
Anticancer Drugs; 2016 Feb; 27(2):89-98. PubMed ID: 26479145
[TBL] [Abstract][Full Text] [Related]
25. Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL.
Rozati S; Cheng PF; Widmer DS; Fujii K; Levesque MP; Dummer R
Clin Cancer Res; 2016 Apr; 22(8):2020-31. PubMed ID: 26660520
[TBL] [Abstract][Full Text] [Related]
26. Global DNA methylation in fetal human germ cells and germ cell tumours: association with differentiation and cisplatin resistance.
Wermann H; Stoop H; Gillis AJ; Honecker F; van Gurp RJ; Ammerpohl O; Richter J; Oosterhuis JW; Bokemeyer C; Looijenga LH
J Pathol; 2010 Aug; 221(4):433-42. PubMed ID: 20593487
[TBL] [Abstract][Full Text] [Related]
27. Histone deacetylase inhibitor romidepsin induces efficient tumor cell lysis via selective down-regulation of LMP1 and c-myc expression in EBV-positive diffuse large B-cell lymphoma.
Shin DY; Kim A; Kang HJ; Park S; Kim DW; Lee SS
Cancer Lett; 2015 Aug; 364(2):89-97. PubMed ID: 25790907
[TBL] [Abstract][Full Text] [Related]
28. Epigenetic drugs and their molecular targets in testicular germ cell tumours.
Jostes S; Nettersheim D; Schorle H
Nat Rev Urol; 2019 Apr; 16(4):245-259. PubMed ID: 30765888
[TBL] [Abstract][Full Text] [Related]
29. Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cell lines.
Hölscher AS; Schulz WA; Pinkerneil M; Niegisch G; Hoffmann MJ
Clin Epigenetics; 2018; 10():1. PubMed ID: 29312470
[TBL] [Abstract][Full Text] [Related]
30. IGF1R signalling in testicular germ cell tumour cells impacts on cell survival and acquired cisplatin resistance.
Selfe J; Goddard NC; McIntyre A; Taylor KR; Renshaw J; Popov SD; Thway K; Summersgill B; Huddart RA; Gilbert DC; Shipley JM
J Pathol; 2018 Feb; 244(2):242-253. PubMed ID: 29160922
[TBL] [Abstract][Full Text] [Related]
31. Histone deacetylase inhibitor, Romidepsin (FK228) inhibits endometrial cancer cell growth through augmentation of p53-p21 pathway.
Li LH; Zhang PR; Cai PY; Li ZC
Biomed Pharmacother; 2016 Aug; 82():161-6. PubMed ID: 27470351
[TBL] [Abstract][Full Text] [Related]
32. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.
Castillo-Avila W; Piulats JM; Garcia Del Muro X; Vidal A; Condom E; Casanovas O; Mora J; Germà JR; Capellà G; Villanueva A; Viñals F
Clin Cancer Res; 2009 May; 15(10):3384-95. PubMed ID: 19417025
[TBL] [Abstract][Full Text] [Related]
33.
Kurz L; Miklyaeva A; Skowron MA; Overbeck N; Poschmann G; Becker T; Eul K; Kurz T; Schönberger S; Calaminus G; Stühler K; Dykhuizen E; Albers P; Nettersheim D
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32272809
[TBL] [Abstract][Full Text] [Related]
34. Cabazitaxel overcomes cisplatin resistance in germ cell tumour cells.
Gerwing M; Jacobsen C; Dyshlovoy S; Hauschild J; Rohlfing T; Oing C; Venz S; Oldenburg J; Oechsle K; Bokemeyer C; von Amsberg G; Honecker F
J Cancer Res Clin Oncol; 2016 Sep; 142(9):1979-94. PubMed ID: 27424191
[TBL] [Abstract][Full Text] [Related]
35. Decreased DHRS2 expression is associated with HDACi resistance and poor prognosis in ovarian cancer.
Han Y; Wang Z; Sun S; Zhang Z; Liu J; Jin X; Wu P; Ji T; Ding W; Wang B; Gao Q
Epigenetics; 2020; 15(1-2):122-133. PubMed ID: 31423895
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of class I histone deacetylases by romidepsin potently induces Epstein-Barr virus lytic cycle and mediates enhanced cell death with ganciclovir.
Hui KF; Cheung AK; Choi CK; Yeung PL; Middeldorp JM; Lung ML; Tsao SW; Chiang AK
Int J Cancer; 2016 Jan; 138(1):125-36. PubMed ID: 26205347
[TBL] [Abstract][Full Text] [Related]
37. Pharmacological or transcriptional inhibition of both HDAC1 and 2 leads to cell cycle blockage and apoptosis via p21
Zhou H; Cai Y; Liu D; Li M; Sha Y; Zhang W; Wang K; Gong J; Tang N; Huang A; Xia J
Cell Prolif; 2018 Jun; 51(3):e12447. PubMed ID: 29484736
[TBL] [Abstract][Full Text] [Related]
38. Romidepsin induces caspase-dependent cell death in human neuroblastoma cells.
Hegarty SV; Togher KL; O'Leary E; Solger F; Sullivan AM; O'Keeffe GW
Neurosci Lett; 2017 Jul; 653():12-18. PubMed ID: 28506690
[TBL] [Abstract][Full Text] [Related]
39. Emerging role of the histone deacetylase inhibitor romidepsin in hematologic malignancies.
Jain N; Odenike O
Expert Opin Pharmacother; 2010 Dec; 11(18):3073-84. PubMed ID: 21080855
[TBL] [Abstract][Full Text] [Related]
40. The Histone Deacetylase Inhibitor Romidepsin Spares Normal Tissues While Acting as an Effective Radiosensitizer in Bladder Tumors in Vivo.
Paillas S; Then CK; Kilgas S; Ruan JL; Thompson J; Elliott A; Smart S; Kiltie AE
Int J Radiat Oncol Biol Phys; 2020 May; 107(1):212-221. PubMed ID: 31987970
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
